[Sequence Listing]

<110>	IMAGENE CO., LTD.	
<120>	Immunological enhancement agent comprising N-terminal pop43 as an effective component	eptide c
<130>	NPF1918	
<160>	11	٠
<170>	KopatentIn 1.71	
<210> <211> <212> <213>	1 147 PRT mammalian	
<400;> Met Ala A 1	1 Asn Asn Asp Ala Val Leu Lys Arg Leu Glu Gln Lys Gly Ala 5 10 1	5
Glu Ala A	usp Gln Ile Ile Glu Tyr Leu Lys Gln Gln Val Ser Leu Leu 20 25 30	
Lys Glu L	ys Ala Ile Leu Gin Ala Thr Leu Arg Glu Glu Lys Lys Leu 35 40 45	
Arg Val G 50	Glu Asn Ala Lys Leu Lys Lys Glu Ile Glu Glu Leu Lys Gln 55 60	
Glu Leu II 65	le Gln Ala Glu Ile Gln Asn Gly Val Lys Gln Ile Ala Phe 70 75	80
Pro Ser Gl	ly Thr Pro Leu His Ala Asn Ser Met Val Ser Glu Asn Val 85 90 9	5
lle Gln Ser	r Thr Ala Val Thr Thr Val Ser Ser Gly Thr Lys Glu Gln 100 105 110	
	y Gly Thr Gly Asp Glu Lys Lys Ala Lys Glu Lys Ile Glu 115 120 125	
Lys Lys G	Gly Glu Lys Lys Glu Lys Lys Gln Gln Ser Ile Ala Gly Ser 135 140	
Ala Asp Se 145	er .	·
<210> <211> <212> <213>	2 108 PRT mammalian	
<400>	2	

	·	
	Met Ala Asn Asn Asp Ala Val Leu Lys Arg Leu Glu Gln Lys Gly Ala 1 5 10	15
•	Glu Ala Asp Gln Ile Ile Glu Tyr Leu Lys Gln Gln Val Ser Leu Leu 20 . 25 30	
	Lys Glu Lys Ala Ile Leu Gln Ala Thr Leu Arg Glu Glu Lys Lys Leu 35 40 45	
	Arg Val Glu Asn Ala Lys Leu Lys Lys Glu Ile Glu Glu Leu Lys Gln 50 55 60	
	Glu Leu Ile Gln Ala Glu Ile Gln Asn Gly Val Lys Gln Ile Ala Phe 65 70 75	80
	Pro Ser Gly Thr Pro Leu His Ala Asn Ser Met Val Ser Glu Asn Val 85 90	95
	Ile Gln Ser Thr Ala Val Thr Thr Val Ser Ser Gly 100 105	•
	<210> 3 <211> 166 <212> PRT <213> mammalian	
	<400> 3 Met Val Ser Glu Asn Val Ile Gln Ser Thr Ala Val Thr Thr Val Ser 1 5 10	15
	Ser Gly Thr Lys Glu Gln Ile Lys Gly Gly Thr Gly Asp Glu Lys Lys 20 25 30	
	Ala Lys Glu Lys Ile Glu Lys Lys Gly Glu Lys Lys Glu Lys Lys Gln 35 40 45	
	Gln Ser Ile Ala Gly Ser Ala Asp Ser Lys Pro Ile Asp Val Ser Arg 50 55 60	
	Leu Asp Leu Arg Ile Gly Cys Ile Ile Thr Ala Arg Lys His Pro Asp 65 70 75	80
	Ala Asp Ser Leu Tyr Val Glu Glu Val Asp Val Gly Glu Ile Ala Pro 85 90	95
	Arg Thr Val Val Ser Gly Leu Val Asn His Val Pro Leu Glu Gln Met 100 105 110	
×	Gln Asn Arg Met Val Ile Leu Leu Cys Asn Leu Lys Pro Ala Lys Met . 115 120 125	
	Arg Gly Val Leu Ser Gln Ala Met Val Met Cys Ala Ser Ser Pro Glu 130 135 140	
	Lys Ile Glu Ile Leu Ala Pro Pro Asn Gly Ser Val Pro Gly Asp Arg 145 150 155	160

212	A ACC 1 L Communication		
<213>	Artificial Sequence		
<220>			
<223>	PCR primer		
	r CR primer		
<400>	8		
	a ataatgat	•	18
	6		_
<210>	9	•	
<211>	18	·	
<212>	DNA		
<213>	Artificial Sequence		
	. 2 2 - 1		
<220>		•	
<223>	PCR primer		
<400>	9		
	aa gcatttta		1
cicgaggg	aa gcaiiiia		1
<210> "	10	•	
<211>	27		
<212>	DNA		
<213>	Artificial Sequence		
	Artificial Sequence	•	
<220>			
<223>	PCR primer		
100	10		
<400>	10		.~
ccggaatte	t ctaagccaat agatgtt		27
<210>	11		•
<211>	27	·	
<212>	DNA		
<213>	Artificial Sequence		•
	Antificial Dequellee		
<220>		•	
<223>	PCR primer		
400		:	
<400>	11	27	,
ccggtcga	ct tatttgattc cactgtt	27	

Ile Thr Phe Asp Ala Phe 165

<210>	4
	27
<211>	
<212>	DNA
<213>	Artificial Sequence
-220-	
<220>	DCD :
<223>	PCR primer
<400>	4
	tggcaaataa tgatgct
ccggaattca	regeadataa tgatget
<210>	5 .
<211>	24
	DNA
<213>	Artificial Sequence
72137	Thursday Soquenes
<220>	
<223>	PCR primer
••	•
<400>	5
ctggtcgacg	g teggeaette eage
<210>	6
<211>	32
<212>	DNA
<213>	Artificial Sequence
000	
<220>	non .
<223>	PCR primer
<400>	6
	-
eggaanear	ggtttctgaa aatgtgatac ag
<210>	7
<211>	30
<212>	DNA
<213>	Artificial Sequence
.4137	
<220>	
<223>	PCR primer
	•
<400>	7

<210> 8 <211> 18

ccggtcgact cagaaagcat caaagtaatt